417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors

Durm, GregoryFrentzas, SophiaRasmussen, ErikNajmi, SaltanatSadraei, Nooshin2022-02-082022-02-082020-11Durm, G., Frentzas, S., Rasmussen, E., Najmi, S., & Sadraei, N. (2020). 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 8(Suppl 3). https://doi.org/10.1136/jitc-2020-SITC2020.0417https://hdl.handle.net/1805/27720enAttribution-NonCommercial 4.0 Internationaladvanced solid tumorsAMG 256 monotherapyphase 1 study417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumorsArticle